SCHEMBL3573308

SCHEMBL3573308

CN1CCN=C1c1ccc(NC(=O)C(c2ccccc2Oc2ccccc2)N(C(N)=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.39
XIAP P98170 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
THRB P10828 1/20 0.36
DGAT1 O75907 1/20 0.34
NPY5R Q15761 1/20 0.34
F2 P00734 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3571907 0.92 F10 (0.41) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3566287 0.88 F10 (0.38) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3558910 0.88 F10 (0.42) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3568352 0.87 F10 (0.42) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3564016 0.86 F10 (0.41) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3571912 0.86 F10 (0.43) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3565553 0.86 F10 (0.41) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3565023 0.86 F10 (0.43) F10ALDH1A1KDM4EMAPTTDP1
SCHEMBL3573310 0.82 UTS2R (0.41) F10XIAPALDH1A1MEN1KMT2A
SCHEMBL3560044 0.82 F10 (0.38) F10ALDH1A1KDM4EMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 F10 9/4885XIAP 2070/4885ALDH1A1 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.